IMCD is a global leader in the distribution and formulation of speciality chemicals and ingredients, providing solutions to its partners.

自成立以来，imcd中国已从最初的采购办事处发展成为一家全面的特种化学品销售和推广公司，在中国设有多个办公室、实验室和仓库，提供了强大的技术和供应链体系。

Operating coast-to-coast in the United States with an extensive portfolio of specialty chemicals and ingredients from leading global producers, the IMCD team delivers market-focused knowledge and worldwide expertise to develop forward reaching solutions that inspire innovation.

Dec 13, 2021 · 12月6日，全球领先的特种化学品和配料分销商imcd n.v.（下称“imcd”）宣布，imcd中国已签署协议，旨在收购上海帝科精细化工有限公司和上海蔚科精细化工有限公司（合称“帝科”）100%的股份。

IMCD has a footprint in over 60 countries in six continents. Each country has a management team that is responsible for the optimisation of our services to customers locally, through our various Business Groups.

Creating a world of opportunity | IMCD is a global leader in the distribution and formulation of speciality chemicals and ingredients, providing solutions to its partners.

3 days ago · Idiopathic multicentric Castleman disease (iMCD) is a rare disease characterized by polyclonal lymphoproliferation and systemic inflammation. Siltuximab, targeting interleukin-6 (IL-6), has been recommended as the first-line therapy for iMCD. However, substantial real-world data from China were still lacking, and treatment for patients with severe iMCD remained challenging. This single-center ...

4 days ago · The pathogenesis of iMCD involves genomic alterations in IL-6/IL-6R loci, oncogenic signaling pathways, epigenetic regulators, and inflammation-related genes. 3-5 Given that IL-6 is the most commonly identified pathological driver of iMCD, the IL-6 antagonist siltuximab is the only Food and Drug Administration (FDA)-approved first-line ...

Consisting of 8 markets, IMCD Nordic provides an extensive global portfolio of specialty chemicals and ingredients together with technical expertise and local knowledge – innovative solutions to all our partners.

2 days ago · 为解决中国特发性多中心 Castleman 病（iMCD）缺乏真实世界数据、重症患者治疗困难的问题，研究人员开展了司妥昔单抗治疗 iMCD 的单中心回顾性研究。结果显示其总体缓解率良好，联合 BCD 方案对重症患者有效，为 iMCD 治疗提供了重要参考。